| 1、出席会议的股东和代理人人数 | 25 | | --- | --- | | 普通股股东人数 | 25 | | 2、出席会议的股东所持有的表决权数量 | 80,361,392 | | 普通股股东所持有表决权数量 | 80,361,392 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 71.6708 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 71.6708 | 证券代码：688358 证券简称：祥生医疗 公告编号：2025-053 无锡祥生医疗科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次会议由公司董事会召集，由董事长、总经理莫若理女士主持。大会采用 （一） ...

上海市通力律师事务所 关于无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会的法律意见书 致: 无锡祥生医疗科技股份有限公司 本所律师已经对公司提供的与本次股东会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有签 署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和有效 的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东会召集和召开的程序、出席本次股东会人员资格 和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见, 并不对 本次股东会所审议的议案内容以及该等议案所表述的事实或数据的真实性和准确性发表意 见。 本所及本所律师依据法律法规及本法律意见出具日以前已经发生或者存在的事实, 严 格履行了法定职责, 遵循了勤勉尽责和诚实信用原则, 进行了充分的核查验证, 保证本法律 意见所认定的事实真实、准确、完整, 所发表的结论性意见合法、准确, 不存在虚假记载、 24SH7200170/WS/kw/cm/D23 上海市通力律师事务所(以下简称"本 ...

Company Overview - Xiangsheng Medical Technology Co., Ltd. is located in Wuxi, Jiangsu Province, and was established on January 30, 1996. The company went public on December 3, 2019. Its main business involves the research, development, manufacturing, and sales of ultrasound medical imaging equipment [1]. - The revenue composition of the company is as follows: 91.12% from ultrasound medical imaging equipment, 6.49% from accessories and others, 2.27% from technical service fees, and 0.12% from other sources [1]. Stock Performance - As of the latest report, Xiangsheng Medical's stock price increased by 1% to 30.29 CNY per share, with a trading volume of 8.7364 million CNY and a turnover rate of 0.26%. The total market capitalization is 3.396 billion CNY [1]. Fund Holdings - The fund "Lobomai China Medical Health Stock Initiation A" (020142) holds a significant position in Xiangsheng Medical, with 47,000 shares, accounting for 6.76% of the fund's net value, making it the fourth-largest holding [2]. - The fund was established on December 26, 2023, with a latest scale of 16.336 million CNY. Year-to-date returns are 17.51%, ranking 2966 out of 4195 in its category, while the one-year return is 15.01%, ranking 3086 out of 4179 [2]. - The fund manager, Li Tao, has been in charge for 2 years and 6 days, with a total asset scale of 22.8582 million CNY. The best and worst fund returns during his tenure are -5.15% and -6.31%, respectively [2].

Core Viewpoint - Despite a decline in both revenue and net profit for 2024, Xiangsheng Medical (688358.SH) continues to face pressure in its performance for the first three quarters of this year, yet has decided to implement a cash dividend to stabilize investor confidence [1][2]. Financial Performance - For the first three quarters of this year, Xiangsheng Medical reported revenue of approximately 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 105 million yuan, down 2.23% [2][3]. - The company's revenue for 2024 was 469 million yuan, reflecting a 3.13% decline, while the net profit decreased by 4.08% to 141 million yuan [2][3]. - The cash dividend proposed is 3 yuan per 10 shares, amounting to a total of 33.56 million yuan, which represents 35.73% of the net profit for the period [2]. Accounts Receivable - As of the end of the third quarter of 2025, Xiangsheng Medical's accounts receivable reached 198 million yuan, an increase of 22% from the previous year, indicating growing pressure on cash flow [3]. Project Delays - Two key fundraising projects, "Research and Innovation and Marketing Operations Base Construction" and "Innovation and Development Reserve Fund," have been postponed to the end of 2026 due to uncontrollable construction factors and quality control needs [1][5]. - The delay in these projects may hinder the company's research and market positioning, impacting its long-term competitiveness [1][5][7]. Market Sentiment - The decision to maintain cash dividends amidst declining performance aims to bolster investor confidence, although previous announcements of significant shareholder reductions have affected market sentiment [3][4].

截至2025年12月26日收盘，祥生医疗(688358)报收于30.1元，下跌0.89%，换手率0.81%，成交量9047.0 手，成交额2726.11万元。 当日关注点 交易信息汇总资金流向 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：12月26日主力资金净流入207.05万元，显示主力对个股短期关注度提升。 来自公司公告汇总：祥生医疗完成2024年限制性股票激励计划首次授予部分第一个归属期股份登 记，涉及26名骨干人员。 12月26日主力资金净流入207.05万元；游资资金净流入58.42万元；散户资金净流出265.47万元。 公司公告汇总祥生医疗2024年限制性股票激励计划首次授予部分第一个归属期归属结果公告 无锡祥生医疗科技股份有限公司完成2024年限制性股票激励计划首次授予部分第一个归属期的股份登 记，本次归属数量为100,860股，来源于公司回购的A股普通股股票，归属对象为26名中层管理人员、技 术骨干及业务骨干，占已获授予权益总额的26.86%。公司股本总数因股份来源为回购股份而不发生变 化。本次 ...

本周关注点 无锡祥生医疗科技股份有限公司完成2024年限制性股票激励计划首次授予部分第一个归属期的股份登 记，本次归属数量为100,860股，来源于公司回购的A股普通股股票，归属对象为26名中层管理人员、技 术骨干及业务骨干，占已获授予权益总额的26.86%。公司股本总数因股份来源为回购股份而不发生变 化。本次归属已完成验资及过户登记手续。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总 无锡祥生医疗科技股份有限公司拟以2025年前三季度实现的归属于上市公司股东净利润为基础，向全体 股东每10股派发现金红利3元（含税），分配总额以权益分派股权登记日登记的总股本扣减回购专用账 户股份数为基数计算，不进行资本公积转增股本和送红股。该方案已由董事会及相关委员会审议通过， 提请股东大会审议。 本次减持计划实施前，祥鼎投资持有祥生医疗4,704,000股，占总股本4.20%；上海御德持有1,679,956 股，占总股本1.50%；祥鹏投资持有1,344,000股，占总股本1.20%。2025年8月29日，公司披露减持计 划，上述 ...

Core Viewpoint - Xiangsheng Medical (688358) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 343 million yuan, a year-on-year decrease of 5.27% [2]. - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year [2]. - The net profit after deducting non-recurring items was 86.97 million yuan, a decrease of 2.69% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 107 million yuan, a decline of 6.68% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 24.22 million yuan, an increase of 41.95% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was 23.14 million yuan, an increase of 53.63% year-on-year [2]. - The company's debt ratio stood at 11.24%, with investment income of 3.01 million yuan and financial expenses of -16.53 million yuan [2]. - The gross profit margin was 59.82% [2]. Market Activity - As of December 26, 2025, Xiangsheng Medical's stock closed at 30.1 yuan, down 0.89%, with a turnover rate of 0.81% and a trading volume of 9,047 hands, amounting to a transaction value of 27.26 million yuan [1]. - On December 26, the net inflow of main funds was 2.07 million yuan, accounting for 7.6% of the total transaction value, while retail investors had a net outflow of 2.65 million yuan, representing 9.74% of the total transaction value [1]. Analyst Ratings - In the last 90 days, three institutions have given buy ratings for Xiangsheng Medical [3].

Group 1 - The core stock price of Xiangsheng Medical (688358) closed at 30.37 yuan on December 25, 2025, with an increase of 1.2% and a turnover rate of 0.64% [1] - The trading volume was 7,114 shares, with a total transaction amount of 21.44 million yuan [1] - On the same day, the main funds experienced a net outflow of 2.6284 million yuan, while speculative and retail funds saw net inflows of 1.864 million yuan and 764,400 yuan, respectively [2] Group 2 - Xiangsheng Medical completed the registration of the first vesting period for its 2024 restricted stock incentive plan, with a total of 100,860 shares vested [1] - The vested shares are allocated to 26 middle-level management, technical, and business backbone personnel, accounting for 26.86% of the total granted rights [1] - The total share capital of the company remains unchanged as the shares are sourced from repurchased A-shares [1]

截至2025年12月25日收盘，祥生医疗（688358）报收于30.37元，较前一交易日上涨1.2%，最新总市值 为34.05亿元。该股当日开盘29.91元，最高30.39元，最低29.77元，成交额达2144.13万元，换手率为 0.64%。 近日，祥生医疗发布《2024年限制性股票激励计划首次授予部分第一个归属期归属结果公告》。公告显 示，公司已完成2024年限制性股票激励计划首次授予部分第一个归属期的股份登记，本次归属数量为 100,860股，来源于公司回购的A股普通股股票，归属对象为26名中层管理人员、技术骨干及业务骨干， 占已获授予权益总额的26.86%。公司股本总数因股份来源为回购股份而不发生变化。本次归属已完成 验资及过户登记手续。 《祥生医疗2024年限制性股票激励计划首次授予部分第一个归属期归属结果公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-052 无锡祥生医疗科技股份有限公司 2024 年限制性股票激励计划首次授予部分 第一个归属期归属结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 本次限制性股票归属数量：100,860 股 本次归属股票来源：无锡祥生医疗科技股份有限公司（以下简称"公司"）回购的 公司 A 股普通股股票 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责任公司上 海分公司（以下简称"中国结算上海分公司"）有关业务规则的规定，公司于近日收到中国 结算上海分公司出具的《过户登记确认书》，公司已完成 2024 年限制性股票激励计划（以 下简称"本激励计划"）首次授予部分第一个归属期的股份登记工作。现将有关情况公告如 下： （www.sse.com.cn）披露了《无锡祥生医疗科技股份有限公司关于公司 2024 年限制性股 票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告》（公告编号： 2024-028）。 5、2024 年 10 ...